Skip to main content

Advertisement

Fig. 5 | Genome Medicine

Fig. 5

From: Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells

Fig. 5

Knockdown of NCOA3 and FOXO3 desensitizes DLD-1 cells to cetuximab. The shRNA knockdown lines of NCOA3, FOXO3, and TCF7L2 in (a) DLD-1 (KRAS G13D) and (b) DLD-1 KRASwt/- genetic backgrounds were treated with cetuximab (20 μg/mL or 40 μg/mL) for 4–5 days. Each experiment was performed three times with eight technical replicates. Mean percentage of Alamar Blue cell viability was normalized to the mean percentage cell viability of untreated control. Mean percentage of viability and SD. Statistical analysis was performed by Student’s t-test where ****P < 0.0001

Back to article page